Literature DB >> 23100224

Generation of an inducible, cardiomyocyte-specific transgenic mouse model with PPAR β/δ overexpression.

Teayoun Kim1, Olga Zhelyabovska, Jian Liu, Qinglin Yang.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) consist of three subtypes, each displaying distinctive tissue distribution. In general, the three PPAR subtypes exert overlapping function in transcriptional regulation of lipid metabolism. However, each PPAR subtype possesses distinctive functions in different tissues dependent on their expression abundance, endogenous ligands, and the PPAR coregulators in a specific tissue. Transgenesis is an invaluable technique in defining the in vivo function of a particular gene and its protein. Cre/LoxP-mediated gene targeting has been extensively used to explore the tissue-specific function of PPARs. While this tissue-specific loss-of-function approach is extremely useful in determining the essential role of a PPAR, the tissue-specific gain-of-function approach is another important technique used to understand the effects of PPAR activation in a particular tissue. Transgenic overexpression of PPAR in a specific tissue has been used. However, this conventional technique requires generating the transgenic models individually for each target tissue. In this chapter, we describe the methodology for a more efficient generation of transgenic mouse models with a constitutively active form of PPARβ/δ in different tissues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23100224      PMCID: PMC3739286          DOI: 10.1007/978-1-62703-155-4_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo.

Authors:  Y Y Kisanuki; R E Hammer; J Miyazaki ; S C Williams; J A Richardson; M Yanagisawa
Journal:  Dev Biol       Date:  2001-02-15       Impact factor: 3.582

2.  Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein.

Authors:  D S Sohal; M Nghiem; M A Crackower; S A Witt; T R Kimball; K M Tymitz; J M Penninger; J D Molkentin
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

3.  Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis.

Authors:  Giuseppe Lo Sasso; Stefania Murzilli; Lorena Salvatore; Ilenia D'Errico; Michele Petruzzelli; Paola Conca; Zhao-Yan Jiang; Laura Calabresi; Paolo Parini; Antonio Moschetta
Journal:  Cell Metab       Date:  2010-08-04       Impact factor: 27.287

4.  Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase.

Authors:  Antje Buerger; Olga Rozhitskaya; Megan C Sherwood; Adam L Dorfman; Egbert Bisping; E Dale Abel; William T Pu; Seigo Izumo; Patrick Y Jay
Journal:  J Card Fail       Date:  2006-06       Impact factor: 5.712

5.  Tamoxifen administration routes and dosage for inducible Cre-mediated gene disruption in mouse hearts.

Authors:  Kristin B Andersson; Lisbeth H Winer; Halvor K Mørk; Jeffery D Molkentin; Frédéric Jaisser
Journal:  Transgenic Res       Date:  2009-11-06       Impact factor: 2.788

6.  Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Authors:  Karen M Stockl; Lisa Le; Shaoang Zhang; Ann S M Harada
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-02       Impact factor: 2.890

7.  Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase.

Authors:  K Araki; M Araki; J Miyazaki; P Vassalli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

8.  PPAR gamma signaling exacerbates mammary gland tumor development.

Authors:  Enrique Saez; John Rosenfeld; Antonia Livolsi; Peter Olson; Eleuterio Lombardo; Michael Nelson; Ester Banayo; Robert D Cardiff; Juan Carlos Izpisua-Belmonte; Ronald M Evans
Journal:  Genes Dev       Date:  2004-03-01       Impact factor: 11.361

9.  Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models.

Authors:  Norimichi Koitabashi; Djahida Bedja; Ari L Zaiman; Yigal M Pinto; Manling Zhang; Kathleen L Gabrielson; Eiki Takimoto; David A Kass
Journal:  Circ Res       Date:  2009-06-11       Impact factor: 17.367

10.  PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization.

Authors:  Shigeki Sugii; Peter Olson; Dorothy D Sears; Maziyar Saberi; Annette R Atkins; Grant D Barish; Suk-Hyun Hong; Glenda L Castro; Yun-Qiang Yin; Michael C Nelson; Gene Hsiao; David R Greaves; Michael Downes; Ruth T Yu; Jerrold M Olefsky; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-16       Impact factor: 11.205

View more
  7 in total

Review 1.  Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function.

Authors:  Greta M P Giordano Attianese; Béatrice Desvergne
Journal:  Nucl Recept Signal       Date:  2015-04-27

2.  Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repair.

Authors:  Ajit Magadum; Yishu Ding; Lan He; Teayoun Kim; Mohankrishna Dalvoy Vasudevarao; Qinqiang Long; Kevin Yang; Nadeera Wickramasinghe; Harsha V Renikunta; Nicole Dubois; Gilbert Weidinger; Qinglin Yang; Felix B Engel
Journal:  Cell Res       Date:  2017-06-16       Impact factor: 25.617

3.  Hepatic PKA inhibition accelerates the lipid accumulation in liver.

Authors:  Jining Yang; Xiaoying Zhang; Long Yi; Ling Yang; Wei Eric Wang; Chunyu Zeng; Mantian Mi; Xiongwen Chen
Journal:  Nutr Metab (Lond)       Date:  2019-10-11       Impact factor: 4.169

4.  High-fat diet activates a PPAR-δ program to enhance intestinal stem cell function.

Authors:  Semir Beyaz; Miyeko D Mana; Ömer H Yilmaz
Journal:  Cell Stem Cell       Date:  2021-04-01       Impact factor: 24.633

5.  Smooth Muscle-Targeted Overexpression of Peroxisome Proliferator Activated Receptor-γ Disrupts Vascular Wall Structure and Function.

Authors:  Jennifer M Kleinhenz; Tamara C Murphy; Anastassia P Pokutta-Paskaleva; Rudolph L Gleason; Alicia N Lyle; W Robert Taylor; Mitsi A Blount; Juan Cheng; Qinglin Yang; Roy L Sutliff; C Michael Hart
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

6.  RUNX1: an emerging therapeutic target for cardiovascular disease.

Authors:  Alexandra Riddell; Martin McBride; Thomas Braun; Stuart A Nicklin; Ewan Cameron; Christopher M Loughrey; Tamara P Martin
Journal:  Cardiovasc Res       Date:  2020-07-01       Impact factor: 10.787

7.  ATP synthase inhibitory factor subunit 1 regulates islet β-cell function via repression of mitochondrial homeostasis.

Authors:  Kailiang Zhang; Rong Bao; Fengyuan Huang; Kevin Yang; Yishu Ding; Lothar Lauterboeck; Masasuke Yoshida; Qinqiang Long; Qinglin Yang
Journal:  Lab Invest       Date:  2021-10-04       Impact factor: 5.502

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.